02898.HK
Sunho Biologics, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 6.40
+0.00%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.1M | 38.0K | 17.5M | 1.7M | 3.2M |
| Cost of Revenue | — | — | 70.0K | 1.3M | — |
| Gross Profit | 2.1M | 38.0K | 138.0K | 473.0K | 3.2M |
| Operating Expenses | |||||
| R&D Expense | 108.9M | 71.1M | 43.0M | 53.2M | 64.0M |
| SG&A Expense | 46.5M | 30.3M | 40.7M | 5.6M | 5.8M |
| General & Admin Expense | 46.5M | 30.3M | 40.7M | 5.6M | 5.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | (12.0M) | — |
| Total Operating Expenses | 155.4M | 101.4M | 83.7M | 46.7M | 69.8M |
| Cost and Expenses | 155.4M | 101.4M | 83.7M | 47.9M | 69.8M |
| Operating Income (EBIT) | (153.4M) | (101.4M) | (66.2M) | (56.9M) | (66.6M) |
| Non-Operating | |||||
| Interest Income | 11.5M | 8.5M | 3.5M | 15.0K | — |
| Interest Expense | — | — | 692.0K | 5.1M | — |
| Net Interest Income | 11.5M | 8.5M | 2.8M | (5.1M) | — |
| Other Non-Op Income/Expense | (22.1M) | 21.4M | (66.5M) | 4.9M | (4.0M) |
| Non-Operating Income (excl Interest) | (14.6M) | — | 65.7M | 707.0K | — |
| EBT (Pre-Tax Income) | (175.5M) | (80.0M) | (132.7M) | (52.0M) | (70.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (175.5M) | (80.0M) | (132.7M) | (52.0M) | (70.6M) |
| Earnings from Cont. Ops | (175.5M) | (80.0M) | (132.7M) | (52.0M) | (70.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (175.5M) | (80.0M) | (132.7M) | (52.0M) | (70.6M) |
| Per Share | |||||
| Basic EPS | (HK$1.49) | (HK$0.62) | (HK$1.43) | (HK$0.57) | (HK$0.78) |
| Diluted EPS | (HK$1.49) | (HK$0.62) | (HK$1.43) | (HK$0.57) | (HK$0.78) |
| Revenue Per Share | HK$0.01 | HK$0.00 | HK$0.19 | HK$0.02 | HK$0.04 |
| Shares | |||||
| Basic Shares Outstanding | 150.9M | 129.0M | 92.9M | 91.2M | 91.0M |
| Diluted Shares Outstanding | 150.9M | 129.0M | 92.9M | 91.2M | 91.0M |
| Profitability Metrics | |||||
| EBITDA | (127.1M) | (95.0M) | (123.4M) | (38.1M) | (64.2M) |
| D&A | 11.7M | 6.4M | 8.6M | 8.8M | 2.4M |
| EBIT | (138.8M) | (101.4M) | (132.0M) | (46.9M) | (66.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2025